Ligelizumab is a humanized IgG1 kappa monoclonal antibody targeting IgE, under investigation for chronic spontaneous urticaria (CSU) treatment. The DrugMonitor™ Anti-Ligelizumab Antibody (VS-1224-YC667) is an anti-drug antibody (ADA) against Ligelizumab. This drug-based antibody is raised in mice immunized with the Ligelizumab. The anti-Ligelizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Ligelizumab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-IGHE ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-755)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human IGHE.
There are currently no Customer reviews or questions for VS-1224-YC667. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.